Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416598 | 0.91 | TSPO (0.42) | TSPOMEN1KMT2A | |
| SCHEMBL416578 | 0.90 | TSPO (0.42) | TSPO | |
| SCHEMBL6688729 | 0.90 | TSPO (0.43) | TSPOL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL12748249 | 0.89 | TSPO (0.43) | TSPOMEN1KMT2AALDH1A1PKM | |
| SCHEMBL12748227 | 0.89 | TSPO (0.43) | TSPOMEN1KMT2AALDH1A1PKM | |
| SCHEMBL12748246 | 0.89 | TSPO (0.43) | TSPOMEN1KMT2AALDH1A1PKM | |
| SCHEMBL15764258 | 0.89 | TSPO (0.43) | TSPOKMT2AALDH1A1PKMMAPT | |
| SCHEMBL460215 | 0.88 | TSPO (0.56) | TSPO | |
| SCHEMBL416930 | 0.85 | TSPO (0.54) | TSPO | |
| SCHEMBL22210606 | 0.82 | LTA4H (0.33) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | GE HEALTHCARE LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| CN-111362863-A | Method for crystallizing tricyclic indole derivative | 通用电气健康护理有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3022178-B1 | ENANTIOMERIC SEPARATION AND PURIFICATION OF 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES | GE HEALTHCARE LTD (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-2552891-B1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| US-9815785-B2 | Enantiomeric separation and purification of 2,3,4,9-tetrahydro-1H-carbazole-4-carboxylic acid amide derivatives | GE HEALTHCARE LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| WO-2014083163-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSPO 50/4885L3MBTL1 4359/4885MEN1 334/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | TSPO 13/4885L3MBTL1 2231/4885MEN1 1142/4885 |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | TSPO 9/4885L3MBTL1 4560/4885MEN1 1550/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | TSPO 72/4885L3MBTL1 3485/4885MEN1 832/4885 |
| US-10709798-B2 | Crystallization process of tricyclic indole derivatives | IDO1, IDO2, TPH1 | TSPO 3643/4885L3MBTL1 3236/4885MEN1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.